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OBJECTIVE—The objective of this study was to determine
whether tolerance to neonatal porcine islet (NPI) xenografts
could be achieved by short-term administrations of anti–LFA-1
and anti-CD154 monoclonal antibodies (mAbs).
RESEARCH DESIGN AND METHODS—Diabetic B6 mice
received NPI transplants and short-term injections of combined
anti–LFA-1 and anti-CD154 mAbs. Mice with long-term islet graft
function were treated with depleting anti-CD25 mAb or re-
transplanted with a second-party NPI. At the end of the study,
grafts from mice with long-term islet function were examined.
Their spleen cells were characterized and used for in vitro
proliferation and adoptive transfer studies.
RESULTS—All mAb-treated NPI recipients maintained normo-
glycemia for 100 days post-transplantation. Only 5 of 50 mice
rejected their grafts before 300 days post-transplantation. Intact
islets, foxp3
 immune cells, as well as interleukin (IL)-10 and
transforming growth factor (TGF)- regulatory cytokine tran-
scripts were detected in the NPI xenografts from tolerant mice.
A higher percentage of CD4
 T-cell population from these mice
expressed regulatory markers, suggesting that tolerance to NPI
xenografts may be mediated by T regulatory cells. This was
conﬁrmed when tolerant mice treated with depleting anti-CD25
mAb became diabetic. Lymphocytes from tolerant mice inhibited
the proliferation of lymphocytes from B6 mice immunized with
porcine cells and they displayed limited proliferation when
adoptively transferred. All protected B6 mice transplanted with a
second-party NPI xenograft maintained long-term normoglyce-
mia even after removal of the ﬁrst NPI graft-bearing kidney.
CONCLUSIONS—These results demonstrate that tolerance to
NPI xenografts can be achieved by transient administrations of
combined anti–LFA-1 and anti-CD154 mAb therapy. Diabetes
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C
urrently, islet transplantation is an alternative
treatment for a very select patient population
and is unavailable to children with type 1 dia-
betes. The limitations to the widespread clinical
application of this treatment are partly due to the severe
shortage of human donor pancreatic tissue (1–3) and the
requirement for continuous use of harmful immunosup-
pressive drugs to prevent rejection of the islet grafts.
Neonatal porcine islets (NPIs) are being considered as an
alternative source of islets for clinical transplantation.
They are easy to maintain in culture and to isolate with
abundant yields (4). In addition, NPIs have the inherent
ability to proliferate, differentiate, and reverse diabetes in
both small (4–6) and large animals (7,8), including the
preclinical nonhuman primate model (8).
The short-term administrations of a combination of
anti–LFA-1 and anti-CD154 monoclonal antibodies (mAbs)
was previously found to be highly effective in preventing
NPI xenograft rejection in B6 mice (5,6), suggesting that
both adhesion and co-stimulatory pathways of T cell
activation are important components of NPI xenograft
rejection. The aim of this study was to determine whether
interference with adhesion and co-stimulatory pathways
by transient administrations of a combination of anti–
LFA-1 and anti-CD154 mAbs could induce tolerance to
phylogenetically disparate NPI xenografts in mice. Our
results show that short-term administrations of this com-
bined mAbs resulted in a robust form of porcine islet
xenograft tolerance mediated by T regulatory cells in B6
mice.
RESEARCH DESIGN AND METHODS
Animals. One- to three-day-old Duroc cross-neonatal pigs (1.5 kg body wt)
from the University of Alberta (Edmonton, AB, Canada) were used as islet
donors. Six- to eight-week-old male B6 (C57BL/6J, H-2
b) and B6 rag
/
(B6.129S7-Rag1
tm1Mom/J, H-2
b) mice from Jackson Laboratory (Bar Harbor,
ME) were used as recipients of islet transplants. These mice were rendered
diabetic by a single intraperitoneal injection of 180 or 175 mg/kg body wt
streptozotocin (Sigma, St. Louis, MO) for B6 or B6 rag
/ mice, respectively.
Blood glucose levels of these mice were measured using a Precision glucose
meter (OneTouch Ultra; LifeScan, Milpitas, CA). All mice were fed standard
laboratory food and cared for according to the guidelines established by the
Canadian Council on Animal Care.
Islet isolation and transplantation. NPIs were isolated and cultured for 7
days in HAM’s F10 medium before transplantation as described previously
(4,5,9). B6 or B6 rag
/ mice that had two consecutive nonfasting blood
glucose levels of 20 mmol/l 4–6 days after streptozotocin injection were
transplanted with 2,000 NPIs as previously described (5,9). The experiments
started with 50 mice, which were monitored for 100 days post-transplantation,
then 40 mice were monitored up to 150 days, and 20 mice were monitored up
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958 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgto 200 days post-transplantation. Finally, 10 mice were monitored up to 250
days post-transplantation, and 8 mice were monitored up to 300 days
post-transplantation. Islet engraftment was considered successful when blood
glucose levels of these mice reached 8.5 mmol/l. Graft rejection was deﬁned
as the ﬁrst of three consecutive days of hyperglycemia (12 mmol/l) and was
conﬁrmed by histological analysis of the graft. Removal of the graft-bearing
kidney was performed in randomly selected recipients with long-term graft
function (150 days post-transplantation) to conﬁrm that maintenance of
normoglycemia was due to the presence of islet xenograft.
Monoclonal antibody therapies. Anti–LFA-1 mAb (KBA; rat IgG2a) was
prepared as ascites and administered intraperitoneally (i.p.) at 200 g on days
0, 1, 7, and 14 post-transplantation. Anti-CD154 mAb (MR-1, hamster IgG;
BioExpress, West Lebanon, NH) was administered intraperitoneally at 250 g
on days 1 and 1 and two times a week for 4 weeks post-transplantation.
Anti-CD25 mAb (PC6.1.5.3, rat IgG1, BioExpress) was injected intraperitone-
ally at 500 g on 0, 2, 4, and 6 days postadministration starting at 150 days
post-transplantation.
Oral glucose tolerance test. At 150 days post-transplantation, an oral
glucose tolerance test was performed in randomly selected B6 and B6 rag
/
mice transplanted with NPI that maintained long-term graft function as
well as in naïve B6 mice (control group) following our previously described
method (4).
Immunohistological analysis. The presence of insulin-producing -cells and
immune cells in the grafts were examined following our published protocol
(5,9). For foxp3 staining, rat anti-mouse foxp3 antibody (1:25 dilutions;
eBioscience, San Diego, CA) and biotinylated goat anti-rat IgG antibody (1:200
dilutions; Southern Biotechnology Associates, Birmingham, AL) were used as
primary and secondary antibody, respectively.
RNA extraction and RT-PCR analysis. mRNA was extracted from NPI
xenograft-bearing kidneys using Trizol reagent following the manufacturer’s
protocol (Invitrogen, Burlington, ON, Canada). cDNA was constructed from 1
g total RNA using Superscript RNase H
 Reverse Transcriptase (Invitrogen)
according to the manufacturer’s protocol, and 1 l cDNA was ampliﬁed for 35
cycles using TaqDNA Polymerase (Invitrogen). The PCR conditions and the
primer sequences were similar to what we have previously published (10).
Positive control includes thymus cDNA from naïve B6 mice, whereas the
negative control includes kidney from these mice and water in place of
experimental cDNA. GAPDH primers (housekeeping gene) ensured the integ-
rity of cDNA, and all the primer pairs spanned at least one intron to make sure
that no genomic DNA was detected during the ampliﬁcation.
Detection of anti-porcine IgG antibodies by ﬂow cytometry. The effect of
combined mAb therapy on the humoral immune responses of B6 and
reconstituted B6 rag
/ mice with NPI xenografts was determined by
measuring the levels of mouse anti-porcine IgG antibodies in the serum
samples of these mice using ﬂow cytometry following our published method
(5,9). Controls for this experiment include porcine spleen cells alone and
porcine spleen cells incubated with the secondary antibody in the absence of
mouse serum.
Characterization of lymphocytes by ﬂow cytometry. Spleens from B6 and
reconstituted B6 rag
/ mice transplanted with NPI were harvested on the
day of rejection or at the end of the study. Spleen cells were isolated (11) and
aliquots of 1  10
6 spleen cells were incubated for 30 min at 4°C with
ﬂuorescent conjugated antibodies (1:100 dilutions; eBioscience, San Diego,
CA) speciﬁc for particular lymphocyte markers. Fluorescence histograms
were created using a BD FACS Calibur ﬂow cytometry machine (BD Bio-
sciences Pharmingen, Mississauga, ON, Canada) and were used to determine
the percentage of positive cells labeled with the corresponding antibodies.
Controls for this experiment include spleen cells from tolerant or naïve B6
mice that were or were not incubated with any of the antibodies.
In vitro proliferation assays. The in vitro proliferation of T-cells (5  10
5)
from naïve or B6 mice transplanted with NPI was determined after stimulation
with Con A (10 g/ml, Sigma), anti-CD3ε mAb (10 g/ml, eBioscience), or
irradiated (2,500 rad) donor neonatal porcine spleen cells (3  10
5 cells)
following our published protocol (11). After 1–6 days (for Con A and
anti-CD3ε mAb stimulation assays) and 3, 4, and 5 days of culture for mixed
lymphocyte reaction assays, T-cell proliferation was determined by pulsing
the cells of primary culture with 1 Ci [
3H]-thymidine/well for 18 h. Cells were
then harvested onto glass microﬁber ﬁlters (Wallac, Turku, Finland), and
counts per minute (CPM) per sample were detected using the Wallac
MicroBeta TriLux luminescence counter (PerkinElmer, Waltham, MA).
Adoptive transfer experiments. At 150 days post-transplantation, spleen
cells from naïve or NPI transplanted B6 mice were either left unlabeled or
labeled with carboxyﬂuorescein diacetate succinimidyl ester (CFSE) accord-
ing to the manufacturer’s protocol (Molecular Probes, Eugene, OR). Fifty
million of these cells in a total volume of 200 l saline were injected into the
peritoneum of naïve or NPI transplanted B6 rag
/ mice. Blood glucose levels
of these mice were monitored three times a week for 60 days post–cell
injection. At the time of rejection or at 60 days post–cell injection if mice
remained normoglycemic, NPI xenografts were harvested and were examined
for the presence of insulin-positive cells as well as immune cells as described
above. The blood glucose levels of B6 rag
/ mice that maintained normo-
glycemia for 60 days post–cell injection were measured after removal of the
kidney bearing the NPI xenograft. A return to the diabetic state was noted, and
spleen cells from these mice were isolated to characterize the adoptively
transferred immune cells using ﬂow cytometry. CFSE-labeled spleen cells
from mouse recipients were also collected and analyzed by ﬂow cytometry
using PE-Cy5–conjugated anti-mouse TCR chain mAb. CFSE-speciﬁc ﬂuo-
rescence histograms were created using a BD FACS Calibur ﬂow cytometry
machine by gating on TCR
 T-cells.
Transplantation of a second-party NPI. Some B6 mice that maintained
normoglycemia for 100 days post-transplantation were re-transplanted with
a second-party NPI under the right kidney capsule. Blood glucose levels of
these mice were monitored for another 100 days (200 days after the ﬁrst NPI
transplant) and, at this time, the left kidney bearing the ﬁrst NPI xenograft was
removed. Blood glucose levels of these mice were measured for an additional
100 days to monitor the function of the second-party NPI xenograft. After 100
days (300 days after transplantation of the ﬁrst NPI), the remaining right
kidney that contained the second NPI xenograft was removed to determine
that maintenance of long-term normoglycemia was due to the presence of the
second-party NPI xenograft.
Statistical analysis. Statistical differences between groups were sought
using Mann-Whitney nonparametric unpaired Student’s t test in SPSS statis-
tical software, version 13.0 for Windows (Chicago, IL). A P value of 0.05 was
considered to be statistically signiﬁcant.
RESULTS
Short-term administrations of a combination of anti–
LFA-1 and anti-CD154 mAbs resulted in indeﬁnite
NPI xenograft survival in B6 mice. To determine if
short-term administrations of a combination of anti–LFA-1
and anti-CD154 mAbs can induce durable NPI xenograft
protection, we lengthened the metabolic follow-up period
of B6 mice up to 300 days post-transplantation. All 50
NPI-transplanted mice treated with the combination of
mAbs achieved normoglycemia within 70–98 days post-
transplantation, whereas none (n  10) of the untreated
NPI recipients achieved normoglycemia (Table 1). At 150
days post-transplantation, which deﬁnes our standard end
point of the study, 39 of 40 treated mice maintained
normoglycemia, and one mouse became diabetic at 105
days post-transplantation. At this time point, the ability of
some treated recipients to respond to glucose challenge in
vivo was performed (Fig. 1A). The blood glucose levels of
these recipients at the beginning of the challenge (time 0
min) and at the end of the challenge (time 90 and 120 min)
were not signiﬁcantly different than those observed in B6
TABLE 1
Survival of NPI xenografts in B6 mice that were not treated or
treated with short-term administrations of a combination of
anti–LFA-1 and anti-CD154 mAbs
n
Graft survival (days
post-transplantation)
% Graft
survival
Group and end point
of the study
(days post-
transplantation)
Untreated group
100 10 0 (10) 0
Treated group
100 50 100 (50) 100
150 40 150 (39), 105 97.5
200 20 200 (18), 160, 185 90
250 10 250 (9), 216 90
300 8 300 (7), 266 85.7
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FIG. 1. Blood glucose levels (BGLs) of B6 mouse recipients of NPI (f) responding to oral glucose challenge at 150 days post-transplantation (A).
Control groups are age-matched B6 rag
/ mouse recipients of the same NPI (F) and naïve nontransplanted B6 mice (Œ). n  5 in each group,
*P < 0.008 versus B6 and B6 rag
/ mouse recipients of NPI. Representative islet grafts from B6 (B) and B6 rag
/ (L) mice that had long-term
normoglycemia contained intact islets with abundant insulin-positive cells (brown stain). Characterization of immune cells surrounding the NPI
xenografts of B6 mice with long-term graft function showed some CD3
, CD4
, CD8
, and foxp3
 cells (brown structures; C–F). Representative
NPI xenografts from B6 mice that became diabetic had no intact islets and contained massive amounts of CD3
 and CD4
 but few CD8
 and
foxp3
 cells (G–K). Scale bar represents 100 m. Higher expression of TGF1 and IL-10 were detected in NPI xenografts from B6 mice with
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/ mouse recipients of the same NPI and naïve B6
mice. However, the blood glucose levels of both B6 and B6
rag
/ mouse recipients of the same NPI were signiﬁ-
cantly lower at the 15-, 30-, and 60-min time points when
compared with naïve B6 mice.
At 200 days post-transplantation, 18 of 20 treated mice
remained normoglycemic while two mice returned to the
diabetic state at 160 and 185 days post-transplantation. Nine
out of 10 treated mice maintained normoglycemia at 250 days
post-transplantation, and one mouse became diabetic at 216
days post-transplantation. Finally, at 300 days post-transplan-
tation, seven of eight treated recipients maintained normo-
glycemia, and one recipient returned to the hyperglycemic
state at 266 days post-transplantation. The removal of the
NPI xenograft-bearing kidney from randomly selected mouse
recipients that maintained long-term normoglycemia at vari-
ous time points post-transplantation resulted in return to the
diabetic state, conﬁrming that maintenance of normoglyce-
mia depends on the islet xenograft.
NPI xenografts from B6 mice with long-term normogly-
cemia (Fig. 1B) showed intact islets composed of abun-
dant insulin-positive cells comparable to those observed in
B6 rag
/ mice transplanted with the same NPI (Fig. 1L).
We observed immune cells surrounding the islet xeno-
grafts in these mice, and further characterization of the
cells revealed that they are CD3
, CD4
, CD8
, and
foxp3
 cells (Fig. 1C–F). In contrast, NPI xenografts from
B6 mice that rejected their NPI xenografts and eventually
became diabetic had massive amounts of immune cell
inﬁltrate with no intact islets remaining in the transplant
site (Fig. 1G) and had few CD8
 and foxp3
 cells (Fig.
1H–K). Analysis of the NPI xenografts harvested from B6
mice with long-term normoglycemia showed higher ex-
pression of transforming growth factor (TGF)-1 and
interleukin (IL)-10 transcripts compared with the expres-
sion observed in B6 mice that eventually rejected their
grafts (Fig. 1M), suggesting that local production of these
regulatory cytokines may be partly responsible for the
protection induced by the combined mAb therapy.
The levels of anti-porcine IgG antibodies in B6 mice that
maintained long-term normoglycemia (Fig. 1N) were compa-
rable to the anti-porcine IgG antibody levels detected in naïve
B6 mice (Fig. 1O). In contrast, the anti-porcine IgG antibody
levels of B6 mouse recipients that eventually rejected the NPI
xenografts were signiﬁcantly higher than the levels detected
in B6 mice that maintained long-term normoglycemia (Fig.
1P). Taken together, these results indicate that short-term
administration of combined anti–LFA-1 and anti-CD154
mAbs induce tolerance to NPI xenografts.
Combined anti–LFA-1 and anti-CD154 mAb therapy
resulted in changes in CD4
 T-cells expressing regu-
latory markers. The total number of immune cells and
frequencies of CD4
, CD8
 T-cells, and CD19
 B-cells
from the spleen of B6 mice that maintained long-term
normoglycemia (tolerant) were comparable to those de-
tected in naïve B6 mice (Table 2). Although the total
number of immune cells and CD19
 B-cells in B6 mice that
eventually rejected the graft (nontolerant) was higher
compared with those detected in tolerant B6 mice and
naïve B6 mice, the difference was not statistically signiﬁ-
cant. In addition, whereas the frequencies of CD4
 and
CD8
 T-cells were lower in nontolerant B6 mice than in
those observed in tolerant B6 and naive B6 mice, the
difference was not statistically signiﬁcant (Table 2). How-
ever, we found signiﬁcant differences in the percentage of
CD4
CD25
 and CD8
CD25
 T-cells between tolerant,
nontolerant, and naïve B6 mice (Fig. 2A). Further analysis
of CD4
CD25
 T-cells showed a signiﬁcant increase in the
frequencies of these cells expressing foxp3 and GITR
compared with those found in nontolerant and naïve B6
mice (Fig. 2B). Similarly, the frequencies of CD4
 T-cells
expressing PD-1 and CTLA-4, but not BTLA co-inhibitory
markers, were also signiﬁcantly increased in tolerant B6
mice compared with those detected in nontolerant and
naïve B6 mice (Fig. 2C). Collectively, these results indicate
that combined anti–LFA-1 and anti-CD154 mAbs result in
higher percentage of CD4
 T-cells expressing regulatory
markers, suggesting that tolerance to NPI xenografts may
be mediated by T regulatory cells.
Combined anti–LFA-1 and anti-CD154 mAb therapy
resulted in T regulatory cell–mediated tolerance to
NPI xenografts. To better deﬁne the role of T regulatory
cells in protection generated by combined anti–LFA-1 and
anti-CD154 mAbs, a group of tolerant B6 mice was treated
with depleting anti-CD25 mAb beginning at 150 days
post-transplantation. All normoglycemic recipients be-
came diabetic at 25.3 	 2.5 days post-injection of anti-
CD25 mAb (n  7, Fig. 3A). NPI xenografts from these
mice had inﬁltrating immune cells and no insulin-positive
cells remaining in the grafts (Fig. 3B). The levels of mouse
anti-porcine IgG antibody in these mice were signiﬁcantly
higher (Fig. 3C) than those detected in tolerant B6 mice
long-term normoglycemia at 150 days post-transplantation (n  8, M) compared with B6 mice that rejected their NPI xenografts (n  2). Positive
control includes thymus cDNA from naïve nontransplanted B6 mice, while the negative controls include kidney from naïve nontransplanted B6
mice and water in place of experimental cDNA. GAPDH serves as a housekeeping gene. The levels of anti-porcine IgG antibodies (solid black line)
in B6 mice that maintained long-term normoglycemia (1.69–5.07%, n  25, N) were comparable to those detected in naïve nontransplanted B6
mice (1.73–4.57%, n  10, O) but were signiﬁcantly (P < 0.001) lower than those detected in B6 mice that eventually rejected the NPI xenografts
(28.54–43.69%, n  5, P). Representative histograms are shown and controls for this experiment consisted of unstained porcine spleen cells
(dashed black line) and porcine spleen cells incubated with a secondary antibody in the absence of mouse serum (solid gray line). (A high-quality
digital representation of this ﬁgure is available in the online issue.)
TABLE 2
Phenotype of immune cells from B6 mouse recipients of NPIs treated with a combination of anti–LFA-1 and anti-CD154 mAbs
compared with the phenotype of immune cells in naÏve non-transplanted B6 mice and B6 mouse recipients of NPIs that rejected their
islet xenografts
n
Mean 	 SE
total number
(10
6)
Mean composition of isolated spleen cells (%) 	 SE
CD4
 CD8
 CD19

Naïve B6 12 89.61 	 2.15 20.98 	 0.82 13.04 	 0.40 55.18 	 2.0
Tolerant B6 19 86.02 	 2.34 20.21 	 0.66 13.32 	 0.47 56.65 	 2.07
Non-tolerant B6 5 94.33 	 4.46 17.91 	 2.50 10.45 	 2.21 61.99 	 6.80
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mice (Fig. 1N and O, respectively). These results further
indicate that T regulatory cells mediate long-term immune
protection of NPI xenografts rendered by combined anti–
LFA-1 and anti-CD154 mAb therapy.
Lymphocytes from tolerant mice suppressed the in
vitro proliferation of porcine-primed lymphocytes in
a dose-dependent manner. Lymphocytes from spleen of
tolerant B6 mice responded robustly after non–antigen-
speciﬁc stimulation with Con A and anti-CD3ε mAb (Fig.
4A). The responses were comparable to the proliferative
responses of lymphocytes from the spleen of naïve B6
mice after adding the same stimulator molecules (Fig. 4B).
Similar to what we have previously reported (12), we
observed no measurable proliferation of lymphocytes
from naïve B6 mice several days after in vitro stimulation
with porcine spleen cells (Fig. 4C). We also found that
lymphocytes from the spleen of tolerant B6 mice did not
proliferate after stimulation with porcine spleen cells from
the islet donor (Fig. 4C). However, we found that initial
priming of naïve B6 mice with porcine spleen cells re-
sulted in strong proliferation of lymphocytes from these
mice when re-stimulated with porcine spleen cells in vitro
(Fig. 4C).
To determine whether lymphocytes from tolerant mice
were capable of suppressing the proliferation of lympho-
cytes from porcine-primed B6 mice, we mixed different
ratios of the two cell populations. Addition of lymphocytes
from tolerant B6 mice resulted in a dose-dependent inhi-
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FIG. 2. High frequency of CD4
 T-cells expressing regulatory markers
were detected in B6 mice with long-term graft function. The frequency
of CD4
CD25
 (2.20  0.08%, n  19, A) and CD8
CD25
 (1.38 
0.09%, n  19) T-cells in B6 mice with long-term graft function () was
signiﬁcantly (P < 0.0001) higher than those observed in naïve non-
transplanted B6 mice (f, 1.58  0.08 and 0.30  0.11%, respectively,
n  12, A) and in B6 mice that rejected their NPI xenografts (p, 1.04 
0.25 and 0.26  0.07%, respectively, n  5, A). In this population, there
were also signiﬁcantly more cells expressing foxp3 (1.29  0.08%, n 
19, P  0.0013, B) and GITR (2.69  0.08%, n  19, P < 0.0001)
compared with those found in naïve nontransplanted B6 mice (0.92 
0.03 and 1.76  0.05%, respectively, n  12) and in B6 mice that
rejected their NPI xenografts (0.43  0.02 and 0.62  0.03%, respec-
tively, n  5). The frequencies of CD4
 T-cells (C) expressing PD-1
(5.12  0.24%, n  19) and CTLA-4 (2.78  0.12%, n  19) but not
BTLA (4.69  0.23%, n  19) co-inhibitory markers were also signiﬁ-
cantly (P < 0.0001) increased in B6 mice with long-term NPI xenograft
survival compared with those detected in naïve nontransplanted B6
mice (3.38  0.63, 0.83  0.18, and 4.79  0.55%, n  12, respectively)
and in B6 mice that became diabetic (2.68  0.13, 0.31  0.06, and
5.01  0.11%, n  5, respectively).
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FIG. 3. T regulatory cells mediate long-term immune protection of NPI
xenografts rendered by combined anti–LFA-1 and anti-CD154 mAb
therapy. All normoglycemic recipients (n  7) that received depleting
anti-CD25 mAb on 0, 2, 4, and 6 days post-administration beginning at
150 days post-transplantation (arrow) became diabetic at 175.3  2.5
days post-transplantation (25.3  2.5 days post-injection of anti-CD25
mAb; A). NPI xenografts had inﬁltrating immune cells and absence of
insulin-positive cells (B). Scale bar represents 100 m. The levels of
mouse anti-porcine IgG antibody (solid black line) in these mice were
signiﬁcantly (P < 0.0001) higher (37.28  1.80%, n  7, C) compared
with the levels detected in tolerant B6 mice that were not treated with
anti-CD25 mAb and in naïve nontransplanted B6 mice (Fig. 1N and O,
respectively). Representative histograms are shown, and controls for
this experiment consisted of unstained porcine spleen cells (dashed
black line) and porcine spleen cells incubated with a secondary
antibody without mouse serum (solid gray line). BGL, XXX; FITC,
ﬂuorescein isothiocyanate. (A high-quality color representation of this
ﬁgure is available in the online issue.)
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primed B6 mice (Fig. 4D). At 1:1, 1:2, 1:4, and 1:8, but not
1:16, ratios of lymphocytes from tolerant B6 mice to
lymphocytes from porcine-primed B6 mice, we observed
signiﬁcant inhibition of proliferation of the latter cell
population at 3 days postculture. In contrast, the addition
of lymphocytes from naïve B6 mice to lymphocytes from
porcine-primed B6 mice at similar ratios did not result in
the inhibition of proliferation but resulted in proliferation
of lymphocytes from porcine-primed B6 mice (data not
shown).
Tolerance rendered by combined anti–LFA-1 and an-
ti-CD154 mAb therapy could be extended to second-
party NPI xenografts. All B6 rag
/ mice transplanted
with ﬁrst- and second-party NPI remained normoglycemic
for 60 days after the transfer of spleen cells from tolerant
B6 mice (Table 3). However, B6 rag
/ mice with estab-
lished NPI xenografts reconstituted with spleen cells from
naïve B6 mice rejected their grafts by 15 days post-cell
transfer (Table 3). CFSE labeling of T-cells from the spleen
of these mice revealed that they exhibited robust prolifer-
ation (Fig. 5A). In contrast, CFSE labeling of T-cells from
B6 mice tolerant to ﬁrst-party NPI xenografts showed that
a large proportion of these cells did not proliferate
strongly after injection into B6 rag
/ mice with estab-
lished ﬁrst-party (Fig. 5B) and second-party (Fig. 5C) NPI
xenografts. However, in the absence of NPI xenografts,
these cells proliferated when injected into naïve B6 rag
/
mice (Fig. 5D).
The ﬁrst-party (Fig. 5E–I) and second-party (Fig. 5J–N)
NPI xenografts from B6 rag
/ mice reconstituted with
spleen cells from tolerant B6 mice had intact islets with
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FIG. 4. Lymphocytes from tolerant mice suppressed the in vitro proliferation of porcine-primed lymphocytes in a dose-dependent manner.
Lymphocytes from tolerant B6 mice (n  9, A) responded robustly after stimulation with Con A () or anti-CD3 mAb (‚) comparable to what
was observed in lymphocytes from naïve nontransplanted B6 mice (f for Con A and Œ for anti-CD3 mAb, n  9, B). Lack of proliferation was
observed when these cells were not stimulated (E for lymphocytes from tolerant mice [A] and F for naïve mice [B]). Lymphocytes from
porcine-primed B6 mice (n  6) responded robustly when stimulated with porcine spleen cells (Œ, C). Lymphocytes from tolerant B6 mice (,
n  9) and naïve nontransplanted B6 mice (F, n  9) did not proliferate after stimulation with porcine spleen cells from the islet donor (C).
Lymphocytes from tolerant B6 mice signiﬁcantly (*P < 0.0005, n  3) inhibited the proliferation of porcine-primed lymphocytes in a
dose-dependent manner on day 3 post-culture (D).
TABLE 3
Survival of ﬁrst- and second-party NPI xenografts in B6 rag
/ mice reconstituted with spleen cells from naïve or tolerant B6 mice
Source of spleen cells n
Graft survival
(days post-cell
transfer)
Source of islets
First- or second-party newborn pig Naïve non-transplanted B6 mice 5 10, 11, 13, 15 (2)
First-party newborn pig B6 mouse recipients with long-term normoglycemia 6 60 (6)
Second-party newborn pig B6 mouse recipients with long-term normoglycemia 7 60 (7)
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FIG. 5. Tolerance provided by combined anti–LFA-1 and anti-CD154 mAb therapy could be extended to second-party NPI xenografts. CFSE
labeling of T-cells from B6 rag
/ mice that rejected the NPI xenografts after reconstitution of spleen cells from naïve B6 mice showed robust
T-cell proliferation (A). In contrast, CFSE labeling of T-cells from B6 mice tolerant to ﬁrst-party NPI xenografts showed that a large proportion
of these cells did not proliferate robustly after injection into B6 rag
/ mice with established ﬁrst-party (B) and second-party (C) NPI
xenografts. However, in the absence of NPI xenografts, these cells were able to proliferate when injected into naïve B6 rag
/ mice (Fig. 5D).
Representative histograms are shown (n  3). Representative ﬁrst-party (E–I) and second-party (J–N) NPI xenografts from B6 rag
/ mice
injected with lymphocytes from tolerant B6 mice had intact islets composed of abundant insulin-positive cells and immune cells such as CD3
,
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CD3
, CD4
, CD8
, and foxp3
 cells. NPI grafts from B6
rag
/ mouse recipients, injected with spleen cells from
naïve B6 mice had no insulin-positive cells and contained
massive immune cellular inﬁltrate (Fig. 5O). The humoral
immune responses in B6 rag
/ mice with ﬁrst-party (Fig.
5P) and second-party (Fig. 5Q) NPI xenografts that main-
tained normoglycemia for 60 days after injection of
spleen cells from tolerant B6 mice were comparable. The
IgG antibody levels of these mice, however, were signiﬁ-
cantly lower than those detected in B6 rag
/ mice that
rejected the NPI xenografts after injection of spleen cells
from naïve B6 mice (Fig. 5R).
To conﬁrm that tolerance to ﬁrst-party NPI xenografts
could be extended to the second-party NPI xenografts,
tolerant B6 mice were re-transplanted with a second-party
NPI. All of the mice transplanted with a second-party NPI
xenograft maintained normoglycemia for 100 days post-
harvest of the ﬁrst-party NPI xenograft. However, removal
of the right kidney bearing the second-party NPI xenograft
resulted in the recurrence of diabetes in all B6 mouse
recipients (Fig. 5S), indicating that tolerance induced by
combined anti–LFA-1 and anti-CD154 mAbs to ﬁrst-party
NPI xenografts could be extended to second-party NPI
xenografts. The ﬁrst-party (Fig. 5T) and second-party (Fig.
5U) NPI xenografts from tolerant B6 mice had intact islets
composed of abundant insulin-positive cells. Low levels of
anti-porcine IgG antibodies (Fig. 5V) were detected in
these mice at the end of the study (300 and 200 days
post-transplantation of the ﬁrst- and second-party NPIs,
respectively).
DISCUSSION
The importance of T regulatory cells in tolerance to NPI
xenografts induced by the combined mAb therapy was
demonstrated when tolerant B6 mice became diabetic
after depletion of CD25
 cells using mAb. We found no
signiﬁcant difference in the total number of spleen cells
and percentage of CD4
, CD8
 T-cells as well as B-cells
from tolerant B6 mice compared with naïve B6 mice,
suggesting that tolerance due to clonal deletion is unlikely.
However, further analysis of the phenotype of immune
cells from tolerant B6 mice using ﬂow cytometry showed
a higher percentage of CD4
 T-cells, co-expressing cell
surface markers for T regulatory cells (13–18) compared
with those observed in naïve B6 mice.
We also showed that T-cells from tolerant B6 mice did
not proliferate after stimulation with porcine spleen cells.
However, they proliferated robustly after non–antigen-
speciﬁc stimulation with Con A or anti-CD3ε mAb, indicat-
ing that the in vitro unresponsiveness observed in T-cells
from tolerant B6 mice is speciﬁc to porcine antigens.
Furthermore, cells from tolerant B6 mice were able to
suppress the proliferative response of lymphocytes from
B6 mice immunized with the same porcine spleen cells
that were used as stimulator cells in the mixed lymphocyte
reaction assays. These results indicate that unresponsive-
ness of T-cells from tolerant B6 mice is not due to their
anergic condition, but could be due to their regulatory
function (19,20). Our results also showed that tolerance to
ﬁrst-party NPI xenografts could be extended to second-
party NPI xenografts, as demonstrated by transfer of
protection to NPI xenografts and survival of second-party
NPI xenografts in tolerant B6 mice, suggesting that the
state of unresponsiveness to islet xenografts may be
species speciﬁc.
Similar to what was recently reported in islet allografts
(21), our study demonstrates that T regulatory cells could
be found in both the graft site and in the secondary
lymphoid organ such as the spleen. These results implicate
that in the case of maintaining tolerance to islet allografts
and xenografts T regulatory cells could control the effector
T-cells in both the sites of ongoing immune response and
in the secondary lymphoid organs. It remains to be deter-
mined, however, whether T regulatory cells could also be
found in the draining lymph nodes as what was shown in
recipients of islet allografts or they are restricted to the
spleen of recipients tolerant to islet xenografts. This will
be an important study in the future to gain a better
understanding of how T regulatory cells exhibit their
suppressive effector function in porcine islet xenograft
recipients.
Another important study in the future is to transplant
porcine islets into nonhuman primates and treat them with
an immunosuppressive protocol that includes simulta-
neous targeting of both adhesion and co-stimulatory path-
ways for T-cell activation. This would test whether our
strategy could also result in tolerance to NPI xenografts in
the presence of preexisting anti-Gal antibodies. Three
recent studies (8,22,23) have demonstrated the feasibility
of porcine islet xenotransplantation in preclinical nonhu-
man primate models, and these studies indicate that
porcine islet xenografts do not undergo Gal-speciﬁc anti-
body-mediated hyperacute rejection, as seen in solid organ
xenografts. However, these studies do not rule out the
possibility that in the absence of Gal antigen, particularly
on NPI, which we have previously demonstrated to highly
expressed 
Gal (24), fewer islets may be required to
reverse hyperglycemia, and less immunosuppression may
be sufﬁcient to demonstrate long-term survival of porcine
islet xenografts. A study comparing the survival of Gal
knockout with wild-type porcine islets in nonhuman pri-
mates using the same immunosuppressive protocol in the
above-mentioned studies or immunosuppressive protocol
that includes our strategy is warranted.
Although we have demonstrated that simultaneous per-
CD4
,CD8
, and foxp3
 cells. NPI xenografts from B6 rag
/ mouse recipients reconstituted with spleen cells from naïve nontransplanted B6
mice had no intact islets (O). The scale bar represents 100 m. The humoral immune responses of B6 rag
/ mouse recipients of ﬁrst-party (P,
n  9) and second-party (Q, n  10) NPI xenografts 60 days after reconstitution with lymphocytes from tolerant B6 mice were comparable (6.31 
0.59 and 7.55  1.02%, respectively). The anti-porcine IgG antibody levels from these mice were signiﬁcantly (P < 0.0001) lower than the IgG
antibody levels detected in B6 rag
/ mice (67.42  5.38%, n  8) reconstituted with lymphocytes from naïve nontransplanted B6 mice, which
rejected the NPI xenografts by 15 days post-cell injection (R). Tolerant B6 mice (n  5) maintained normoglycemia after re-transplantation of
a second-party NPI xenograft (ﬁrst arrow, S) and remained normoglycemic after removal of the ﬁrst-party NPI xenograft (second arrow). These
mice became diabetic only after removal of the right kidney bearing the second-party NPI xenograft (third arrow). Representative ﬁrst-party (T)
and second-party (U) NPI xenografts from tolerant B6 mice had intact islets composed of abundant insulin-positive cells. Scale bar represents
100 m. Low levels of anti-porcine IgG antibodies (3.95  0.52%, n  5) were detected in these mice at the end of the study (>300 and >200 days
post-transplantation of the ﬁrst- and second-party NPI, respectively; V). Representative histograms of porcine spleen cells bound to mouse IgG
antibodies are shown, and controls for this experiment consisted of unstained porcine spleen cells (dashed black line) and porcine spleen cells
incubated with a secondary antibody without mouse serum (solid gray line). BGL, blood glucose level; FITC, ﬂuorescein isothiocyanate. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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for T-cell activation are highly effective at inducing toler-
ance to NPI xenografts in immune-competent mice, it is
important to demonstrate that this strategy could be
equally effective in an animal model of type 1 diabetes. We
previously reported that combined anti–LFA-1 and anti-
CD154 mAbs could also be effective at prolonging the
survival and function of NPI xenografts in spontaneously
diabetic NOD mice if CD4
 T-cells were initially depleted
(9). This suggests that in individuals with type 1 diabetes,
targeting the autoreactive memory T-cell population may
be required in addition to interfering with the adhesion
and co-stimulatory pathways of T-cell activation to
achieve long-term survival of porcine islet xenografts.
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